Will Clarivate's IP segment achieve sustained positive ACV growth (>1%) by H2 2026?

IP segment ACV is near flat (~0%), recovered from -3% decline. New leadership (Mourad from Verisk, joined Sep 2025) needs time to implement changes — typically 6-12 months before strategic shifts impact ACV. The AI-driven patent filing surge provides a 2-3 year tailwind for the annuity book, but annuity renewals are a lagging indicator. Getting ACV above 1% by H2 2026 requires improvement in both renewals and new business — aggressive given the starting point. New leadership may not show material impact until 2027.

The IP segment is fundamentally a mature business — patent annuity management, trademark search, and patent analytics. These are not high-growth categories. The recovery from -3% to flat was driven by stabilization, not acceleration. Moving from flat to >1% requires either meaningful new product adoption (AI tools in IP) or pricing power expansion — both of which are uncertain. The CPA Global acquisition burdened this segment with integration costs and distraction. Even with a strong new leader, transforming a flat-growth $800M segment in under a year is ambitious.

The patent annuity tailwind from AI-driven filing surge is the most compelling growth driver. If AI truly increases patent filing volumes (plausible — more inventions, faster drafting), the CPA Global annuity book grows mechanically as those patents enter the renewal pipeline. This is a 2-3 year tailwind that could push ACV above 1%. Additionally, Derwent Innovation is well-positioned for AI-enhanced patent search — a genuine value-add. The question is timing: will this show in ACV by H2 2026? Possibly, given patent filings increased through 2025.

IP ACV near flat after years of decline signals structural challenges. New leadership is promising (Mourad has domain expertise from Verisk) but 6 months is insufficient to drive ACV above 1%. Patent annuity renewals are compliance-driven and sticky but slow-moving. The bar is sustained >1%, not a one-off — consistent ACV acceleration requires multiple quarters of improvement. More likely a 2027 story.

Company-wide ACV guidance is 2-3% for FY2026. If A&G delivers 3-4% ACV growth (plausible given momentum), IP could remain flat and the company still hits guidance. This suggests management does not depend on IP inflection for guidance achievement. However, the AI patent tailwind and new leadership create optionality. The question asks for Q3 or Q4 reporting — giving time for momentum to build. 40% probability reflects genuine optionality but not base case.

The IP segment has been a laggard for years. CPA Global integration disrupted the business, and organic growth has been negative or flat since the acquisition. Even with recovery to flat, the structural challenge is that patent annuities are a utility-like business — they grow with the installed base of patents, not with new product innovation. Moving ACV from flat to >1% in this segment requires either (a) significant pricing actions, (b) meaningful new product ACV from AI tools, or (c) patent filing volume driving annuity base growth. All three are possible but none is the base case for H2 2026.

IP ACV at flat, new leadership 6 months in, structurally mature segment. AI patent tailwind is real but lagging. More likely a 2027 inflection than H2 2026. Below 35%.

Patent filing surge from AI creates a genuine growth driver for the annuity book. New leadership from Verisk brings domain expertise. But structural maturity of the segment and CPA Global integration baggage make >1% ACV by H2 2026 a stretch. Slightly above one-third probability.

Flat ACV moving to >1% in a mature, compliance-driven segment within 6-9 months is aggressive. Patent annuity growth is slow-moving. The question is whether this is a 2026 or 2027 story — the weight of evidence says 2027. 30% probability.